Table 1. Association between galectin-1 and disease-free survival in renal cell carcinoma patients.
| HRa | 95% CIb | P-value | |
|---|---|---|---|
|
Univariate analysis | |||
|
Galectin-1 statusc | |||
| Low expression | 1.00 | ||
| High expression |
2.03 |
1.038–3.99 |
0.039 |
| Tumor size (ordinal) |
1.18 |
1.064–1.31 |
0.002 |
| Sex |
2.74 |
0.78–9.56 |
0.11 |
| Stage (ordinal) |
2.57 |
1.47–4.49 |
0.001 |
|
Multivariate analysisd | |||
| Galectin-1 statusc | |||
| Low expression | 1.00 | ||
| High expression |
2.08 |
1.049–4.11 |
0.036 |
| Tumor Size (ordinal) |
1.13 |
0.99–1.28 |
0.055 |
| Sex |
1.65 |
0.44–6.17 |
0.45 |
| Stage (ordinal) | 1.86 | 1.00–3.45 | 0.048 |
Abbreviations: CI=confidence interval; HR=hazard ratio.
a
HR estimated from Cox proportional hazard regression model.
b
CI of the estimated HR.
c
Low Expression: cytoplasmic frequency (1–2); High expression: cytoplasmic frequency (3–4).
d
Multivariate models were adjusted for patient stage, sex and tumor size.